Evolution of the Synthetic Process to Prepare the Tripeptide Segment of ABT-510
Part of the Advances in Experimental Medicine and Biology book series (volume 611)
ABT-510 is a thrombospondin-1 mimetic currently in Phase 2 clinical trials as an angiogenesis inhibitor for treatment of cancer. An efficient synthetic process was developed by the Process R&D group at Abbott and has been scaled to produce several 10 kg batches of the drug substance.
KeywordsReverse Osmosis Ammonium Chloride Catalytic Hydrogenation Thionyl Chloride Hydrophobic Interaction Chromatography
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
© Springer Science+Business Media, LLC 2009